TICKERNERD
Menu
PYPDPYPDHealthcare · Biotechnology

PYPD Stock Forecast: PolyPid Ltd. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$4.36
+1.63% on the day

The 4 Wall Street analysts covering PolyPid Ltd. hold a median 12-month price target of $13 — +186.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 1 Aug 2026 — in the lower half.

Market cap
$82.3M
Ticker Nerd rank
43 / 100
Median analyst target
$13
Analysts covering
4
Total return, dividends reinvested
1W
+9.5%
1M
−13.1%
YTD
+0.5%
1Y
+27.9%
From 52W high
−21.9%
From 52W low
+38.4%
$3.15
$5.58
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PYPD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PolyPid Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
91
Volatility
90
Size
77
Momentum
60
Revisions
43
Growth
41
Value
31
Accruals
24
Quality
13

Issuance (91): The share count has been shrinking and the company is not leaning on new borrowing.

Quality (13): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

The rank is the raw material. Whether the rules would actually own PolyPid Ltd. — and when they’d sell — is the membership.

Wall Street

PYPD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PYPD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Oct 25Jan 26Apr 26Jul 26PYPDHigh $14Median $13Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $9Median $13High $14

The green dot is the last close — the median target sits +186.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 July 2026HC Wainwright & Co.ReiteratesBuy$13
11 Feb 2026HC Wainwright & Co.ReiteratesBuy—
11 Feb 2026HC Wainwright & Co.ReiteratesBuy$13
13 Nov 2025Roth CapitalMaintainsBuy—
14 Aug 2025Craig-HallumMaintainsBuy—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
18 June 2025Roth CapitalMaintainsBuy—
17 June 2025JMP SecuritiesMaintainsMarket Outperform—
9 June 2025HC Wainwright & Co.MaintainsBuy—
5 June 2025Roth CapitalInitiatesBuy—
2 June 2025HC Wainwright & Co.AssumesBuy$11
14 Apr 2025HC Wainwright & Co.ReiteratesBuy—
26 Dec 2024HC Wainwright & Co.MaintainsBuy—
16 Dec 2024HC Wainwright & Co.ReiteratesBuy—
4 Nov 2024Craig-HallumInitiatesBuy—
2 Oct 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
18 June 2024HC Wainwright & Co.ReiteratesBuy—
9 May 2024HC Wainwright & Co.ReiteratesBuy—
1 May 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

PYPD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

PolyPid Ltd. (PYPD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.1×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
9.4×

Cheaper than 11% of US stocks

EV / EBITDA
−2.3×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−758.6%

Higher than 2% of US stocks

Return on assets
−115.1%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PYPD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PYPDPolyPid Ltd.$82.3M
43
BMEABiomea Fusion, Inc.$82.7M
46
GOSSGossamer Bio, Inc.$82.9M
32
TELOTelomir Pharmaceuticals, Inc.$83.2M
17
RLYBRallybio Corp.$84.1M
58
CGTXCognition Therapeutics, Inc.$78.5M
33
NRXSNeurAxis, Inc.$77.4M
48
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PYPD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest PYPD news & analysis

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

GlobeNewsWire · 30 July 2026neutral

PolyPid Ltd. announced it will report its second quarter 2026 financial results and operational highlights before U.S. markets open on August 12, 2026, and will hold a conference call and webcast at 8:30 AM ET that day to discuss the results and business operations.

Why it matters — The announcement provides the date and time for PolyPid's quarterly update, which will include financial results and an operational overview that shareholders and analysts will be watching.

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

GlobeNewsWire · 29 July 2026positive

PolyPid announced that the U.S. FDA has accepted its New Drug Application (NDA) for D-PLEX₁₀₀ and granted Priority Review, with a PDUFA target action date of November 28, 2026 — roughly one quarter ahead of the company's prior guidance.

Why it matters — FDA acceptance with Priority Review moves D-PLEX₁₀₀ a step closer to potential U.S. approval, and the faster-than-expected review timeline could shorten the wait for a regulatory decision.

FAQ

Frequently asked questions about PYPD stock

What is the PYPD stock price forecast for 2026-2027?

The 4 Wall Street analysts covering PolyPid Ltd. have a median 12-month price target of $13, with estimates ranging from $9 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PYPD stock a buy right now?

Of the 4 analysts covering PolyPid Ltd., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PolyPid Ltd. 43 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PYPD?

As at 1 Aug 2026, PolyPid Ltd. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (91 of 100).

Will PYPD stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +186.7% from the last close, and Ticker Nerd's factor model ranks PolyPid Ltd. 43 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PYPD stock forecast for 2030?

No analyst covering PolyPid Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PYPD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $14 over the next 12 months.

How has PYPD stock performed over the past year?

PolyPid Ltd. returned +27.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PolyPid Ltd. do?

PolyPid Ltd. is an innovative biopharmaceutical company developing long-acting, controlled-release medicines that deliver therapy precisely at the site of care.

What is the latest news on PYPD?

The most recent item we track (GlobeNewsWire, 30 July 2026): "PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026". PolyPid Ltd. announced it will report its second quarter 2026 financial results and operational highlights before U.S. markets open on August 12, 2026, and will hold a conference call and webcast at 8:30 AM ET that day to discuss the results and business operations.

Company

About PolyPid Ltd.

PolyPid Ltd. is an innovative biopharmaceutical company developing long-acting, controlled-release medicines that deliver therapy precisely at the site of care. It specializes in locally administered therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) and Kynatrix technologies, which enable precise, localized drug delivery at predetermined rates over days to months. The lead product candidate, D-PLEX100, provides prolonged antibiotic exposure directly at surgical sites to prevent surgical site infections, particularly in abdominal colorectal surgeries. PolyPid Ltd. also advances applications of its platform in oncology, obesity, diabetes, and other high-impact indications, including a long-acting GLP-1 receptor agonist delivery system. The company maintains a GMP-certified manufacturing facility supporting commercial-scale production. Founded in 2008 and headquartered in Petah Tikva, Israel, PolyPid Ltd. focuses on improving patient outcomes in surgical care, metabolic diseases, and beyond through targeted precision drug delivery.

CEO Ms. Dikla Czaczkes Akselbrad · 69 employees · Israel · https://www.polypid.com